Updated Mar. 3, 2014 at 5:47 a.m.

Premium Lock Scynexis files for $55M IPO, banks on antifungal returned by Merck

Published: 2014-02-28 09:47:00
Updated: 2014-03-03 05:47:53

Print this blog post
The Scynexis pipeline The Scynexis pipeline, from the Scynexis website Image 1 of 2 · Next Image…

Scynexis originally partnered with drug giant Merck in 2002 to develop and commercialize a compound called SCY-078. Merck chose to return it last year. Now, Scynexis sees the compound as key to helping it pull off a public offering of stock. It is targeting a $3.6 billion market. So what makes the compound so special?...

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll